Role of TSH Inhibition Therapy in the Postoperative Management of Patients with Differentiated Thyroid Cancer

Proceedings of Anticancer Research Pub Date : 2024-04-12 DOI:10.26689/par.v8i2.6295

Xudong Gao, Bo Zhao, Ya Su, Shenglin He

{"title":"Role of TSH Inhibition Therapy in the Postoperative Management of Patients with Differentiated Thyroid Cancer","authors":"Xudong Gao, Bo Zhao, Ya Su, Shenglin He","doi":"10.26689/par.v8i2.6295","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the effect of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer. Methods: Seventy patients diagnosed with differentiated thyroid cancer were selected for the study. TSH inhibition therapy was administered to the research group, while thyroxine replacement therapy was provided to the control group during the postoperative management phase. This allowed for a comparative analysis between the two groups. Results: In comparison with the control group, the research group exhibited significant decreases in serum TSH, T3, and T4 levels after treatment, while FT4 and FT3 levels significantly increased (P < 0.05). Additionally, significant decreases in Tg, VEGF, TSGF, CD44V6, and sIL-2R levels were observed in the research group after treatment (P < 0.05). No significant differences were found in pre-treatment thyroid function between the two groups (P > 0.05). Conclusion: The application of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer demonstrates promising outcomes.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v8i2.6295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the effect of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer. Methods: Seventy patients diagnosed with differentiated thyroid cancer were selected for the study. TSH inhibition therapy was administered to the research group, while thyroxine replacement therapy was provided to the control group during the postoperative management phase. This allowed for a comparative analysis between the two groups. Results: In comparison with the control group, the research group exhibited significant decreases in serum TSH, T3, and T4 levels after treatment, while FT4 and FT3 levels significantly increased (P < 0.05). Additionally, significant decreases in Tg, VEGF, TSGF, CD44V6, and sIL-2R levels were observed in the research group after treatment (P < 0.05). No significant differences were found in pre-treatment thyroid function between the two groups (P > 0.05). Conclusion: The application of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer demonstrates promising outcomes.

查看原文本刊更多论文

TSH 抑制疗法在分化型甲状腺癌患者术后管理中的作用

目的研究 TSH 抑制疗法在分化型甲状腺癌患者术后治疗中的效果。研究方法选取 70 名确诊为分化型甲状腺癌的患者作为研究对象。在术后治疗阶段，研究组采用 TSH 抑制疗法，对照组采用甲状腺素替代疗法。这样就可以对两组患者进行比较分析。结果与对照组相比，研究组治疗后血清 TSH、T3 和 T4 水平显著下降，而 FT4 和 FT3 水平显著上升（P < 0.05）。此外，研究组的 Tg、VEGF、TSGF、CD44V6 和 sIL-2R 水平在治疗后明显下降（P < 0.05）。两组患者治疗前的甲状腺功能无明显差异（P > 0.05）。结论在分化型甲状腺癌患者的术后治疗中应用 TSH 抑制疗法具有良好的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Proceedings of Anticancer Research

自引率

0.00%

发文量